Domainex Supports NRG Therapeutics Programme Resulting in the Nomination of Development Candidate, NRG5051

We are delighted that NRG Therapeutics has achieved a key milestone with the nomination of its first development candidate, NRG5051, and has secured a $5 million award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Domainex is proud to have supported this project by providing integrated lead optimization services including assay biology and medicinal and computational chemistry. During the period that Domainex worked on the programme, through careful design, we were able to make significant enhancements to the in vivo PK profiles of the lead series and ultimately identify NRG5051 as the development candidate.